It remains unclear whether there is clinical utility for withholding chemotherapy in HR+/HER2-, node-positive breast cancer based upon the 21-gene Recurrence Score. While we await the results from randomized, phase III trials, this editorial addresses additional observational data that suggest there may be a role for this genomic assay in this patient population.